# Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd: Phase 1 study in Hepatic Impairment (25 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Pharmacokinetics and Safety of Levornidazole Disodium Phosphate for Injection in Chinese Patients With Hepatic Impairment |
| NCT ID | NCT07906171 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Hepatic Impairment |
| Intervention types | drug |
| Target enrollment | 25 |
| Site countries | China |
| Posted | 2026-10-30 |
| Planned start | 2023-09-15 |
| Event | Newly registered study |
| Event date | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07906171). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.